Alfuzosin - CAS 81403-80-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alfuzosin
Catalog Number:
81403-80-7
Synonyms:
Alfuzosina;Alfuzosine;Xatral;2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-;N-[3-[N-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-N-(methyl)amino]propyl]tetrahydrofuran-2-carboxamide;SL 77499;Alfuzosinum
CAS Number:
81403-80-7
Description:
Alfuzosin is a pharmaceutical drug of the alpha-1 blocker class. It works by relaxing the muscles in the prostate and bladder neck. It is used to treat benign prostatic hyperplasia (BPH). It offers an alternative to prostatectomy in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. It is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing.
Molecular Weight:
389.45
Molecular Formula:
C19H27N5O4
Quantity:
Grams to Kilograms
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI:
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChIKey:
WNMJYKCGWZFFKR-UHFFFAOYSA-N
Targets:
Adrenergic Receptor
Current Developer:
Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing.
Chemical Structure
CAS 81403-80-7 Alfuzosin

Related Adrenergic Receptor Products


Etiguanfacine
(CAS: 1346686-31-4)

Etiguanfacine is a α2-Adreno Receptor agonist using for the treatment of ADHD (Attention deficit hyperactivity disorder).

CAS 147568-66-9 Carmoterol

Carmoterol
(CAS: 147568-66-9)

Carmoterol, a quinolin derivative, has been found to a β2-adrenoceptor agonist that could be an effective bronchodilating agent.

CAS 610309-89-2 Carvedilol Phosphate

Carvedilol Phosphate
(CAS: 610309-89-2)

Carvedilol phosphate hemihydrate is a nonselective beta (β1, β2) blocker and alpha (α1) blocker, inhibits LDL oxidation (IC50 = 3.8 μM).

CAS 312753-06-3 Indacaterol

Indacaterol
(CAS: 312753-06-3)

Indacaterol Maleate is an ultra-long-acting β-adrenoceptor agonist.

CAS 32780-64-6 labetalol hydrochloride

labetalol hydrochloride
(CAS: 32780-64-6)

Labetalol HCl is a dual antagonist for both selective alpha1-adrenergic and nonselective beta-adrenergic receptors, used in the treatment of high blood pressure...

CAS 522-48-5 Tetrahydrozoline Hydrochloride

Tetrahydrozoline Hydrochloride
(CAS: 522-48-5)

Tetrahydrozoline HCl is an imidazoline derivative with alpha receptor agonist activity.

CAS 65576-45-6 Asenapine

Asenapine
(CAS: 65576-45-6)

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug by combining serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related ...

CAS 54-80-8 Pronetalol

Pronetalol
(CAS: 54-80-8)

Pronethalol is a non-selective beta-adrenergic blocking agentused in treatment due to carcinogenic properties.

CAS 71576-40-4 Aptazapine

Aptazapine
(CAS: 71576-40-4)

Aptazapine is a tetracyclic antidepressant. It was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed. Aptazapine is...

CAS 29110-48-3 Guanfacine HCl

Guanfacine HCl
(CAS: 29110-48-3)

Guanfacine HCl is the hydrochloride salt of Guanfacine. Guanfacine, a selective agonist of α2A receptor, is a sympatholytic drug to treat attention deficit hype...

CAS 770-05-8 DL-Octopamine hydrochloride

DL-Octopamine hydrochloride
(CAS: 770-05-8)

Octopamine hydrochloride is an α-adrenoceptor agonist.

CAS 81047-99-6 CGP 12177

CGP 12177
(CAS: 81047-99-6)

CGP 12177 is a partial β3-adrenoceptor agonist with Ki value of 88 nM. It is also an of β1- and β2-adrenoceptors antagonist with Ki values of 0.9 nM and 4 nM fo...

CAS 67339-62-2 ARC239 dihydrochloride

ARC239 dihydrochloride
(CAS: 67339-62-2)

ARC239 dihydrochloride is a potent and selective α2 B adrenoceptor antagonist. It is used as an α-adrenoceptor blocking drug. It competitively antagonizes press...

MK-0634
(CAS: 211031-01-5)

MK-0634, also called as L-796568, is an β3 adrenergic receptor agonist that was progressed into clinical studies for the treatment of obesity in the early 2000s...

VIBEGRON
(CAS: 1190389-15-1)

This active molecular is a selective Beta 3 Adrenergic Receptor Agonist and was developed by Kyorin Pharmaceutical for the treatment of OAB (Overactive Bladder)...

CAS 23256-50-0 Guanabenz Acetate

Guanabenz Acetate
(CAS: 23256-50-0)

Guanabenz Acetate is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respe...

CAS 5985-28-4 Synephrine Hydrochloride

Synephrine Hydrochloride
(CAS: 5985-28-4)

SynephrineHCl (Oxedrine, p-Synephrine) is a sympathomimetic α-adrenergic receptor (AR) agonist.

CAS 104344-23-2 Bisoprolol fumarate

Bisoprolol fumarate
(CAS: 104344-23-2)

Bisoprolol is a beta-adrenoceptor blocking drug (beta-blocker). More specifically, it is a selective type β1 adrenergic receptor blocker.

CAS 27912-14-7 Levobunolol hydrochloride

Levobunolol hydrochloride
(CAS: 27912-14-7)

Levobunolol hydrochloride, a beta1- and beta2-adregergic blocking agent, has proved to be an effective ocular hypotensive agent to treat glaucoma.

SNAP-8719 HCl
(CAS: 255893-38-0)

SNAP-8719, structurally very similar to BMY-7378, is a selective, orally active α1D-AR antagonist with lower binding affinity for the 5-HT1A receptor.

Reference Reading


1.Assessment of column selection systems using Partial Least Squares.
Žuvela P1, Liu JJ2, Plenis A3, Bączek T3. J Chromatogr A. 2015 Nov 13;1420:74-82. doi: 10.1016/j.chroma.2015.09.085. Epub 2015 Oct 1.
Column selection systems based on calculation of a scalar measure based on Euclidean distance between chromatographic columns, suffer from the same issue. For diverse values of their parameters, identical or near-identical values can be calculated. Proper use of chemometric methods can not only provide a remedy, but also reveal underlying correlation between them. In this work, parameters of a well-established column selection system (CSS) developed at Katholieke Universiteit Leuven (KUL CSS) have been directly correlated to parameters of selectivity (retention time, resolution, and peak/valley ratio) toward pharmaceuticals, by employing Partial Least Squares (PLS). Two case studies were evaluated, separation of alfuzosin, lamotrigine, and their impurities, respectively. Within them, comprehensive correlation structure was revealed, which was thoroughly interpreted, confirming a causal relationship between KUL parameters and parameters of column performance.
2.Formulation and evaluation of gastroretentive controlled release tablets of alfuzosin hydrochloride.
Rudraswamy-Math NR1, Gupta VR1. Pak J Pharm Sci. 2015 Nov;28(6):2147-52.
Alfuzosin hydrochloride is a novel drug used in the treatment of urinary incontinency. The purpose of this research was to develop controlled release floating matrix formulations of Alfuzosin HCl. Floating matrix tablets of Alfuzosin HCl were prepared using hydroxypropyl methylcellulose (HPMC), Polyethylene oxide (PEO), Carbopol 971P NF polymer (Direct compressible) and Blend of Polyvinyl Acetate and Povidone 30 (80:19:1(0.8% sodium laury sulfate and 0.2% silica)). Combination of citric acid and sodium bicarbonate were also used as gas forming agent. Matrix formulations were prepared by direct compression method and evaluated for floating, in vitro drug release profile and swelling characteristics. The mechanism of drug release was found to follow non-Fickian or anomalous type. The data obtained from the invitro release studies demonstrated that the floating matrix tablets containing HPMC 100K CR (controlled-release) and carbopol along with sodium CMC were found to sustain the release of drug over a period of 12 hours.
3.Temperature influencing permeation pattern of alfuzosin: an investigation using DoE.
Pattnaik S1, Swain K2, Rao JV2, Varun T2, Mallick S3. Medicina (Kaunas). 2015;51(4):253-61. doi: 10.1016/j.medici.2015.07.002. Epub 2015 Jul 30.
BACKGROUND AND OBJECTIVE: There has been relatively little investigation of the effect of temperature on skin permeation compared to other methods of penetration enhancement. A principal physicochemical factor which controls the passive diffusion of a solute from a vehicle into the skin arises from the skin temperature. The aim of this ex vivo study was to probe into the effect of heat on transdermal absorption of alfuzosin hydrochloride from ethyl cellulose-polyvinyl pyrrolidone (EC-PVP) based transdermal systems.
4.Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A1, Anoopkumar-Dukie S2, Chess-Williams R1, McDermott C1. Prostate. 2016 Feb 16. doi: 10.1002/pros.23167. [Epub ahead of print]
BACKGROUND: Some α1 -adrenoceptor antagonists possess anti-cancer actions that are independent of α1 -adrenoceptors and the aim of these studies was to assess the relative cytotoxic potencies of α1 -adrenoceptor antagonists and the mechanisms involved in these actions.